Usage Examples
- The moiety was approved in a 1998 NDA, so this reformulation gets no NCE — only the 3-year clock is available to us.
- Build the launch model off year four, not year five; a Paragraph IV filer can submit the day the four-year window opens.
- Regulatory confirmed NCE at approval, which is why FDA refused to receive the generic's ANDA last month.
What is New Chemical Entity Exclusivity (NCE)?
New Chemical Entity Exclusivity is a five-year FDA marketing exclusivity awarded on the first approval of a drug whose active moiety has never been approved, blocking ANDA and 505(b)(2) submissions rather than merely their approval.
New Chemical Entity exclusivity exists because a sponsor that proves a never-before-approved active moiety is safe and effective carries the entire cost of that first demonstration, while every follow-on applicant can rely on it. Congress answered with a fixed five-year window in which FDA will not even accept a generic or 505(b)(2) filing on that moiety.
New Chemical Entity exclusivity covers only drug products approved in an NDA after September 24, 1984 whose active moiety FDA has approved in no other 505(b) NDA. It does not cover new formulations, strengths, or indications of an already-approved moiety; it does not attach to biologics, which are licensed outside section 505; and it grants no rights against another sponsor's full 505(b)(1) NDA.
New Chemical Entity exclusivity is worked in practice as date arithmetic run alongside patent terms. Regulatory teams calculate the five-year bar and the four-year Paragraph IV opening from the approval date, add the 30-month stay measured from notice of certification, and compare the result against patent expiry. Whichever runs longer sets the real launch date; exclusivity and patents run independently.
Not to be confused with
- 3-year exclusivity
- 3-year exclusivity bars FDA from approving a competing ANDA or 505(b)(2), but does not stop one being submitted. New Chemical Entity exclusivity bars the submission itself, which is why it is the stronger of the two.
- Patents
- a patent is granted by USPTO and enforced by the holder in court against an infringer. New Chemical Entity exclusivity is granted by FDA and enforced by FDA declining to receive an application. A product can have one without the other.
- New Molecular Entity (NME)
- NME is a CDER review classification for a drug FDA has not previously approved. It is a review-tracking designation, not a legal bar on competitors, and an NME approval does not by itself establish New Chemical Entity exclusivity.
- Orphan-drug exclusivity
- orphan-drug exclusivity attaches to a designated rare-disease use, not to the novelty of the active moiety, so a moiety FDA approved decades ago can still earn it for a new orphan indication.
New Chemical Entity exclusivity is not something a sponsor applies for; it is a determination FDA makes at approval. These are the obligations that follow from it.
What you must do
- 1Confirm before claiming New Chemical Entity status that the product contains no active moiety FDA has approved in any other NDA submitted under section 505(b)21 CFR 314.108(a)
- 2Count the five-year bar on ANDA and 505(b)(2) submissions for the same active moiety from the date of approval of the first approved NDA, not from launch, not from the later approval of a line extension21 CFR 314.108(b)(2)
- 3Plan for competing applications to arrive at four years where they carry a certification of patent invalidity or noninfringement, and size the litigation reserve against that date21 CFR 314.108(b)(2)
- 4Track the 30-month period from receipt of the notice of certification by the patent owner or the NDA holder, because that clock, not the exclusivity clock, often controls the competitor's approval date; where suit is brought in the year beginning four years after approval, approval can move to 7½ years from NDA approval21 CFR 314.107(b)(3)
- 5Claim 3-year exclusivity separately for any application or supplement whose approval rested on new clinical investigations, other than bioavailability studies, conducted or sponsored by the applicant and essential to approval21 CFR 314.108(b)(4)
Common mistakes
Assuming a reformulation, new strength, or new indication resets the five-year clock
the statutory test looks at whether the active moiety has been approved in any other 505(b) NDA, not at whether the product is new. Lifecycle plans built on a second round of New Chemical Entity exclusivity collapse the day FDA receives a generic filing that should have been blocked.
Treating New Chemical Entity exclusivity as a substitute for patent coverage
New Chemical Entity exclusivity blocks a category of applications; it confers no right to sue anyone. A product with five years of exclusivity and no patent estate faces a competitor's full 505(b)(1) NDA on the same moiety with no remedy at all.
Forecasting generic entry at year five
the operative date is year four plus litigation, because a Paragraph IV filer may submit twelve months early. Commercial models anchored to the five-year number consistently overstate the protected revenue window and understate the legal spend that lands in year four.
When This Matters
- The moiety was approved in a 1998 NDA, so this reformulation gets no NCE — only the 3-year clock is available to us.
- Build the launch model off year four, not year five; a Paragraph IV filer can submit the day the four-year window opens.
- Regulatory confirmed NCE at approval, which is why FDA refused to receive the generic's ANDA last month.
Frequently Asked Questions
A drug qualifies only if it contains no active moiety that FDA has already approved in another NDA under section 505(b). The test runs on the active moiety rather than the finished product, so a new formulation or strength of an already-approved moiety fails it.
Related Use Cases
- Pharma Use Cases
Cut NDA and sNDA prep time by 60% with AI-assisted drafting and automated readiness checks
- Biotech Use Cases
Compress IND prep from 8-12 weeks to under 3 weeks with AI-assisted drafting and validation
- Regulatory Affairs Workflows
Cut regulatory intelligence tracking from 10+ hours/week to automated, real-time alerts
- CMC Workflows
Track ICH quality guidelines automatically and get alerts when changes impact your products
